Dobrin Svinarov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dobrin Svinarov has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Milena Velizarova
Department of Clinical Laboratory , Medical University , Sofia , Bulgaria
4 shared publications - Julieta Hristova
Department of Clinical Laboratory and Drug Toxicity , Aleksandrovska University Hospital , Faculty of Medicine, Medical University – Sofia , Bulgaria
2 shared publications - Ana-Maria Simundic
Department of Medical Laboratory Diagnostics, University Hospital ‘Sveti Duh’, 10000 Zagreb, Croatia
1 shared publication - Anastasiya Mihaylova
Department of Clinical Immunology and Stem Cell Bank University Hospital Alexandrovska Sofia Bulgaria
1 shared publication - Anna Linko-Parvinen
Turku University Hospital
1 shared publication - Atanas Yonkov
Department of General and Hepato-Pancreatic Surgery, University Hospital "Alexandrovska" - Sofia; Medical University – Sofia, Bulgaria
1 shared publication
Latest Publications
- Open Access
- 31 July 2023
- Published by Prof. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences) in Proceedings of the Bulgarian Academy of Sciences
- Vol. 76 (7) , 1092-1099
Dynamics of Immunological and Biochemical Markers Depends on the Severity and Time after Symptoms Onset of COVID-19 – Single Centre Analysis
- 31 July 2023
- Published by Prof. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences) in Proceedings of the Bulgarian Academy of Sciences
- Vol. 76 (7) , 1092-1099
Open AccessDynamics of Immunological and Biochemical Markers Depends on the Severity and Time after Symptoms Onset of COVID-19 – Single Centre Analysis
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#3750 SERUM AMYLOID A AS PROGNOSTIC MARKER FOR CKD AND NON-CKD COVID-19 PATIENTS ADMITTED TO THE EMERGENCY ROOM
Patients with chronic kidney disease (CKD) and a SARS-CoV-2 infection are at higher risk of developing acute kidney injury (AKI) and of mortality after hospital admission. Herein, we assessed whether serum amyloid A (SAA) was associated with outcomes (AKI and/or death). The study group included 160 patients: 70 Covid-19-positive CKD patients (eGFR 38oC. Overall, creatinine level on admission was elevated in 40% of cases; eGFR was 2 in 37.5% of patients. Mean value of eGFR on admission was 82.3 mL/min/1.73 m2 for the non-CKD Covid-19-positive group, 49.5 mL/min/1.73 m2 for the CKD Covid-19-positive group, 62.3 mL/min/1.73 m2 for the CKD patients without COVID-19, and 111.1 mL/min/1.73 m2 for the healthy control group. In total, three Covid-19 patients needed renal-replacement therapy: two patients from the CKD group and one from the non-CKD group. AKI occurred in 38 Covid-19 patients (23.7%). Of these, 31 had CKD (44.3% of the Covid-19 positive CKD patients). Overall, within our cohort of 160 patients, in-hospital mortality was 14.3% (23 patients): of these, 82.6% had AKI (19 patients). Overall, 100% of patients that did not survive Covid-19 also had CKD. We analyzed the levels of SAA across the groups. The reference limits considered for negative results were 300 pg/ml (82.6%), whilst the remainder had results >250 pg/mL. The other patients who survived the infection in our cohort had levels well below 200 pg/ml. When the patients with AKI and without AKI were compared on the basis of SAA, patients with AKI had significantly higher biomarker values (p- = 0.02). When compared across the four groups, no significant differences were found except when comparing the healthy control group with the other three groups, where there was significance of p<0.0001 in each comparison. We confirm that SAA was a reliable biomarker for predicting AKI in Covid-19 patients. It also acted as a predictor for a fatal outcome in patients with severely Covid-19 infection. In conclusion, SAA is a reliable marker, highly informative in the emergency department setting, enabling us to have an early prognosis for the outcome of the Covid-19 infection for the patients in our cohort.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#3750 SERUM AMYLOID A AS PROGNOSTIC MARKER FOR CKD AND NON-CKD COVID-19 PATIENTS ADMITTED TO THE EMERGENCY ROOM
Patients with chronic kidney disease (CKD) and a SARS-CoV-2 infection are at higher risk of developing acute kidney injury (AKI) and of mortality after hospital admission. Herein, we assessed whether serum amyloid A (SAA) was associated with outcomes (AKI and/or death). The study group included 160 patients: 70 Covid-19-positive CKD patients (eGFR 38oC. Overall, creatinine level on admission was elevated in 40% of cases; eGFR was 2 in 37.5% of patients. Mean value of eGFR on admission was 82.3 mL/min/1.73 m2 for the non-CKD Covid-19-positive group, 49.5 mL/min/1.73 m2 for the CKD Covid-19-positive group, 62.3 mL/min/1.73 m2 for the CKD patients without COVID-19, and 111.1 mL/min/1.73 m2 for the healthy control group. In total, three Covid-19 patients needed renal-replacement therapy: two patients from the CKD group and one from the non-CKD group. AKI occurred in 38 Covid-19 patients (23.7%). Of these, 31 had CKD (44.3% of the Covid-19 positive CKD patients). Overall, within our cohort of 160 patients, in-hospital mortality was 14.3% (23 patients): of these, 82.6% had AKI (19 patients). Overall, 100% of patients that did not survive Covid-19 also had CKD. We analyzed the levels of SAA across the groups. The reference limits considered for negative results were 300 pg/ml (82.6%), whilst the remainder had results >250 pg/mL. The other patients who survived the infection in our cohort had levels well below 200 pg/ml. When the patients with AKI and without AKI were compared on the basis of SAA, patients with AKI had significantly higher biomarker values (p- = 0.02). When compared across the four groups, no significant differences were found except when comparing the healthy control group with the other three groups, where there was significance of p<0.0001 in each comparison. We confirm that SAA was a reliable biomarker for predicting AKI in Covid-19 patients. It also acted as a predictor for a fatal outcome in patients with severely Covid-19 infection. In conclusion, SAA is a reliable marker, highly informative in the emergency department setting, enabling us to have an early prognosis for the outcome of the Covid-19 infection for the patients in our cohort.
- Open Access
- 10 March 2023
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 37 (1)
Relationship between Vitamin D status and microbiome changes in Bulgarian patients with type 2 diabetes mellitus
- 10 March 2023
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 37 (1)
Open AccessRelationship between Vitamin D status and microbiome changes in Bulgarian patients with type 2 diabetes mellitus
- Open Access
- 1 September 2022
- Published by Bulgarian Surgical Society in ITEGAM-Journal of Engineering and Technology for Industrial Applications (ITEGAM-JETIA)
- Vol. 86 (3) , 107-115
Use of indocyanine green for liver function assessment and its role in predicting the risk of postoperative liver failure
Postoperative liver failure (POLF) is one of the most serious complications in abdominal surgery, as its appearance is often associated with an unfavorable outcome.OBJECTIVE: To investigate the role of Indocyanine Green (ICG) and Indocyanine Green Retention rate (ICG-R15) for assessment of liver function in order to predict the risk of POLF.MATERIAL AND METHODS: In 06.2021 – 11.2022, a prospective study was conducted, including 20 patients admitted in University Hospital "Alexandrovska" for malignant liver neoplasms. Liver function was assessed by static biochemical parameters and intravenous ICG administration (0.5 mg/kg), aiming to measure the residual blood concentration at the 15th minute (ICG-R15). The results and the probable correlation with clinico-morphological features were processed statistically.RESULTS AND DISCUSSION: The study included 13 men (65%) and 7 women (35%) with primary (5) and metastatic (15) liver tumors. 13 minor (15%, major liver interventions were not undertaken (p=0.001). In the ICG-R15 <15% group, regardless of major resection performed, POLF was not observed. The lack of significant deviations in static liver indicators with marked differences in ICGR15 clearly shows the need to combine methods for a precise liver function assessment. POLF was rapidly controlled due to consideration of the resection volume in context of ICG-R15.CONCLUSION: The ICG-R15 is an easy, safe, and valuable tool for assessing liver function and identifying patients at risk of POLF. Additional studies are needed, as the present study is initial for Bulgaria.
- 1 September 2022
- Published by Bulgarian Surgical Society in ITEGAM-Journal of Engineering and Technology for Industrial Applications (ITEGAM-JETIA)
- Vol. 86 (3) , 107-115
Open AccessUse of indocyanine green for liver function assessment and its role in predicting the risk of postoperative liver failure
Postoperative liver failure (POLF) is one of the most serious complications in abdominal surgery, as its appearance is often associated with an unfavorable outcome.OBJECTIVE: To investigate the role of Indocyanine Green (ICG) and Indocyanine Green Retention rate (ICG-R15) for assessment of liver function in order to predict the risk of POLF.MATERIAL AND METHODS: In 06.2021 – 11.2022, a prospective study was conducted, including 20 patients admitted in University Hospital "Alexandrovska" for malignant liver neoplasms. Liver function was assessed by static biochemical parameters and intravenous ICG administration (0.5 mg/kg), aiming to measure the residual blood concentration at the 15th minute (ICG-R15). The results and the probable correlation with clinico-morphological features were processed statistically.RESULTS AND DISCUSSION: The study included 13 men (65%) and 7 women (35%) with primary (5) and metastatic (15) liver tumors. 13 minor (15%, major liver interventions were not undertaken (p=0.001). In the ICG-R15 <15% group, regardless of major resection performed, POLF was not observed. The lack of significant deviations in static liver indicators with marked differences in ICGR15 clearly shows the need to combine methods for a precise liver function assessment. POLF was rapidly controlled due to consideration of the resection volume in context of ICG-R15.CONCLUSION: The ICG-R15 is an easy, safe, and valuable tool for assessing liver function and identifying patients at risk of POLF. Additional studies are needed, as the present study is initial for Bulgaria.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 36 (sup1) , S1-S4
Editorial
Dear Colleagues,It is our great pleasure to welcome you to the special supplement issue of Biotechnology & Biotechnological Equipment presenting the proceedings of the Joint XXVIII Balkan Clinical ...
- 1 January 2022
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 36 (sup1) , S1-S4
Open AccessEditorial
Dear Colleagues,It is our great pleasure to welcome you to the special supplement issue of Biotechnology & Biotechnological Equipment presenting the proceedings of the Joint XXVIII Balkan Clinical ...
- Open Access
- 12 May 2020
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (3) , 505-512
A proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications)
European Union (EU) Directive 2013/55/EC (The Recognition of Professional Qualifications) allows Member States to decide on a common set of minimum knowledge, skills and competences that are needed to pursue a given profession through a Common Training Framework. To be adopted the framework must combine the knowledge, skills and competences of at least one third of the Member States. Professionals who have gained their qualifications under a Common Training Framework will be able to have these recognised automatically within the Union. The backbone of the European Federation of Clinical Chemistry and Laboratory Medicine’s (EFLM) proposed Common Training Framework for non-medical Specialists in Laboratory Medicine is outlined here. It is based on an Equivalence of Standards in education, training, qualifications, knowledge, skills, competences and the professional conduct associated with specialist practice. In proposing the recognition of specialist practice EFLM has identified 15 EU Member States able to meet Equivalence and in whom the profession and/or its training is regulated (an additional EU Commission requirement). The framework supports and contributes to the Directive’s enabling goals for increasing professional mobility, safeguarding consumers and ensuring a more equitable distribution of skills and expertise across the Member States. It represents EFLM’s position statement and provides a template for professional societies and/or competent authorities to engage with the EU Commission.
- 12 May 2020
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (3) , 505-512
Open AccessA proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications)
European Union (EU) Directive 2013/55/EC (The Recognition of Professional Qualifications) allows Member States to decide on a common set of minimum knowledge, skills and competences that are needed to pursue a given profession through a Common Training Framework. To be adopted the framework must combine the knowledge, skills and competences of at least one third of the Member States. Professionals who have gained their qualifications under a Common Training Framework will be able to have these recognised automatically within the Union. The backbone of the European Federation of Clinical Chemistry and Laboratory Medicine’s (EFLM) proposed Common Training Framework for non-medical Specialists in Laboratory Medicine is outlined here. It is based on an Equivalence of Standards in education, training, qualifications, knowledge, skills, competences and the professional conduct associated with specialist practice. In proposing the recognition of specialist practice EFLM has identified 15 EU Member States able to meet Equivalence and in whom the profession and/or its training is regulated (an additional EU Commission requirement). The framework supports and contributes to the Directive’s enabling goals for increasing professional mobility, safeguarding consumers and ensuring a more equitable distribution of skills and expertise across the Member States. It represents EFLM’s position statement and provides a template for professional societies and/or competent authorities to engage with the EU Commission.
- Open Access
- 1 August 2015
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (8) , e62-e63
Determination of Methylphenidate In Human Plasma By A Validated Lc-Ms/Ms Method
- 1 August 2015
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (8) , e62-e63
Open AccessDetermination of Methylphenidate In Human Plasma By A Validated Lc-Ms/Ms Method
- Open Access
- 1 December 2014
- Published by Walter de Gruyter GmbH in BANTAO Journal
- Vol. 12 (2) , 114-118
Vitamin D Status has no Influence on the Incidence of Recurrent Urinary Tract Infections after Kidney Transplantation
Introduction. Recurrent urinary tract infections (rUTIs) after kidney transplantation (KT) are associated with significant decrease in graft survival. There is a growing body of evidence for the pleiotropic effects of vitamin D (VD), including immunomodulatory and antibacterial effect. The number of studies on VD’s pleiotropic effects in kidney transplant recipients (KTRs) however is low. The aim of our study was to assess the influence of VD on the incidence of recurrent UTIs after KT. Methods. The KTRs were tested for 25-hydroxyvitamin D (25VD) between 1.05.2012 and 30.11.2012. Patients within 12 months of transplantation, performed parathyroidectomy, concomitant intake of calcineurin inhibittors and mTOR inhibitors, advanced liver disease and VD supplementation were excluded from the study. Recurrent UTIs were defined as more than 3 episodes of active UTI within the last 12 months of testing for 25VD. Statistical analysis was carried out with SPSS version 22.0 and included descriptive statistics, Mann-Whitney U test. Determination of total 25VD was performed by a validated LC-MS/MS method. Results. A total of 275 patients met the above-mentioned criteria (males 182, females 93). The mean 25VD in patients with rUTIs (n=14) was 51.41±25.17 nmol/L, whereas in the group without rUTIs (n=261) the level was 60.35±23.29 nmol/L. After matching the two groups for seasonal factors (sampling for 25VD in July, August, September) and gender 169 patients were selected, and 11 were with rUTIs. No significant difference was detected in the 25VD level in the two groups (53.30±18.37 vs 49.08±21.04 nmol/L), p=0.342. Conclusions. Despite the higher 25VD in the KTRs without rUTIs, the difference between the two groups remained insignificant.
- 1 December 2014
- Published by Walter de Gruyter GmbH in BANTAO Journal
- Vol. 12 (2) , 114-118
Open AccessVitamin D Status has no Influence on the Incidence of Recurrent Urinary Tract Infections after Kidney Transplantation
Introduction. Recurrent urinary tract infections (rUTIs) after kidney transplantation (KT) are associated with significant decrease in graft survival. There is a growing body of evidence for the pleiotropic effects of vitamin D (VD), including immunomodulatory and antibacterial effect. The number of studies on VD’s pleiotropic effects in kidney transplant recipients (KTRs) however is low. The aim of our study was to assess the influence of VD on the incidence of recurrent UTIs after KT. Methods. The KTRs were tested for 25-hydroxyvitamin D (25VD) between 1.05.2012 and 30.11.2012. Patients within 12 months of transplantation, performed parathyroidectomy, concomitant intake of calcineurin inhibittors and mTOR inhibitors, advanced liver disease and VD supplementation were excluded from the study. Recurrent UTIs were defined as more than 3 episodes of active UTI within the last 12 months of testing for 25VD. Statistical analysis was carried out with SPSS version 22.0 and included descriptive statistics, Mann-Whitney U test. Determination of total 25VD was performed by a validated LC-MS/MS method. Results. A total of 275 patients met the above-mentioned criteria (males 182, females 93). The mean 25VD in patients with rUTIs (n=14) was 51.41±25.17 nmol/L, whereas in the group without rUTIs (n=261) the level was 60.35±23.29 nmol/L. After matching the two groups for seasonal factors (sampling for 25VD in July, August, September) and gender 169 patients were selected, and 11 were with rUTIs. No significant difference was detected in the 25VD level in the two groups (53.30±18.37 vs 49.08±21.04 nmol/L), p=0.342. Conclusions. Despite the higher 25VD in the KTRs without rUTIs, the difference between the two groups remained insignificant.